Amir Hassan
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1548357312
Payments from drug & device makers
Across 926 payments — averaging $5573.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3.5M
- AbbVie$1.2M
- Amgen$121K
- Novo Nordisk AS$79K
- Biogen$63K
- Sanofi-aventis U.S. LLC$43K
- plus $106K from 50 others
Across 14 payments — averaging $24,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$338K
What the payments were for
- Consulting fees$2,9259%
- Speaking & faculty fees$20,38861%
- Travel & lodging$1,3814%
- Food & beverage$8,52125%
- Education$2651%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,161,356 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 782 | $1,322,600 |
| MounjaroTirzepatide | 293 | $451,614 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 258 | $336,346 |
| JardianceEmpagliflozin | 185 | $261,302 |
| VascepaIcosapent Ethyl | 196 | $185,923 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 129 | $178,656 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $176,739 |
| FarxigaDapagliflozin Propanediol | 129 | $169,857 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 123 | $161,803 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $121,683 |
| GlyxambiEmpagliflozin/Linagliptin | 68 | $100,103 |
| JanuviaSitagliptin Phosphate | 55 | $64,243 |
| Xigduo XrDapaglifloz Propaned/Metformin | 43 | $52,011 |
| TradjentaLinagliptin | 32 | $44,122 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $41,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $709 | $1,353,535819 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Glyxambi, Tradjenta | $31,711 | $933,781689 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $13,772 | $511,458349 claims |
| MerckJanumet Xr, Januvia | $366 | $226,045178 claims |
| AstraZenecaFarxiga | $250 | $169,857129 claims |
| Esperion Therapeutics, Inc.Nexlizet | $136 | $18,51516 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $71 | $15,59217 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $76 | $15,277924 claims |
| AbbVieSynthroid | $1,210,416 | $13,796172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Amer Al KaradshehHouston$8.8M
- Camilo JimenezHouston$5M
- Rocio HarbisonHouston$3.2M
- Gerardo BuesoHouston$1.2M
- Veena WatweHouston$976K
- Andres SplenserHouston$923K
- Prashant KoshyHouston$795K
- Laila TabatabaiHouston$780K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.